RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.
Adenocarcinoma
/ pathology
Animals
Apoptosis
/ drug effects
Cell Line, Tumor
Colonic Neoplasms
/ pathology
Epigenesis, Genetic
/ genetics
Gene Expression Regulation, Neoplastic
/ drug effects
Gene Silencing
Heterografts
Histone Deacetylase 1
/ genetics
Histone Deacetylase Inhibitors
/ pharmacology
Humans
Mice
MicroRNAs
/ genetics
Nuclear Receptor Subfamily 4, Group A, Member 1
/ genetics
Receptors, Retinoic Acid
/ genetics
Signal Transduction
Tretinoin
/ metabolism
butyrate
nuclear receptor
propionate
protein deacetylase
short-chain fatty acid
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
27
9
2018
medline:
1
10
2019
entrez:
26
9
2018
Statut:
ppublish
Résumé
This study investigates the mechanism and consequences of microRNA-22 ( miR-22) induction. Our data revealed for the first time that retinoic acid (RA) and histone deacetylase (HDAC) inhibitors, including short-chain fatty acids and suberanilohydroxamic acid (SAHA), could individually or in combination induce miR-22. This induction was mediated via RA receptor β (RARβ) binding to a direct repeat 5 (DR5) motif. In addition, we uncovered HDAC1 as a novel miR-22 target. In an miR-22-dependent manner, HDAC inhibitors and RA reduced HDAC1, HDAC4, and sirtuin 1 (SIRT1), which were involved in chromatin remodeling of the RARβ and nerve growth factor IB ( NUR77). Thus, HDAC inhibitors and RA-induced miR-22 resulted in simultaneous induction of cytoplasmic RARβ and NUR77, leading to apoptosis of colon cancer cells. In mice, miR-22 and its inducers inhibited the growth of xenograft colon cancer. Moreover, tumor size reduction was accompanied by elevated miR-22, NUR77, and RARβ and by reduced HDACs. In human colon polyps and adenocarcinomas, miR-22 and RARβ were consistently reduced, which was associated with elevated HDAC1, HDAC4, and SIRT1 in colon adenocarcinomas. Results from this study revealed a novel anticancer mechanism of RARβ via miR-22 induction to epigenetically regulate itself and NUR77, providing a promising cancer treatment modality using miR-22 and its inducers.-Hu, Y., French, S. W., Chau, T., Liu, H.-X., Sheng, L., Wei, F., Stondell, J., Garcia, J. C., Du, Y., Bowlus, C. L., Wan, Y.-J. Y. RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.
Identifiants
pubmed: 30252536
doi: 10.1096/fj.201801390R
pmc: PMC6338632
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
MIRN22 microRNA, human
0
MicroRNAs
0
NR4A1 protein, human
0
Nuclear Receptor Subfamily 4, Group A, Member 1
0
Receptors, Retinoic Acid
0
retinoic acid receptor beta
0
Tretinoin
5688UTC01R
HDAC1 protein, human
EC 3.5.1.98
Histone Deacetylase 1
EC 3.5.1.98
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2314-2326Subventions
Organisme : NCI NIH HHS
ID : R01 CA222490
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA179582
Pays : United States
Références
Int J Oncol. 2017 Feb;50(2):345-355
pubmed: 28000852
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7421-6
pubmed: 24799697
Hum Mol Genet. 2012 May 15;21(10):2157-65
pubmed: 22328083
Proc Nutr Soc. 2008 May;67(2):115-27
pubmed: 18412986
Oncol Rep. 2015 Oct;34(4):1771-8
pubmed: 26239725
Carcinogenesis. 2012 Feb;33(2):301-11
pubmed: 22159226
Mol Cancer Res. 2015 Feb;13(2):281-92
pubmed: 25232032
FEBS J. 2010 Apr;277(7):1684-94
pubmed: 20180843
Genes Chromosomes Cancer. 2009 Jun;48(6):521-31
pubmed: 19306352
Exp Biol Med (Maywood). 2014 Nov;239(11):1489-504
pubmed: 24951470
Mol Cell Biol. 2003 Dec;23(23):8651-67
pubmed: 14612408
J Cell Physiol. 2011 Feb;226(2):322-30
pubmed: 20836077
Front Immunol. 2013 Aug 01;4:226
pubmed: 23914191
Biochem Pharmacol. 2010 Sep 15;80(6):867-73
pubmed: 20438716
Oncology. 2007;72(1-2):69-74
pubmed: 18004079
Adv Drug Deliv Rev. 2010 Oct 30;62(13):1285-98
pubmed: 20654663
Mol Cancer Res. 2014 Apr;12(4):527-538
pubmed: 24515801
J Pharmacol Exp Ther. 2009 Feb;328(2):469-77
pubmed: 18981289
Mol Cell Biol. 2017 Aug 28;37(18):
pubmed: 28674186
Redox Biol. 2017 Aug;12:340-349
pubmed: 28288414
FASEB J. 2011 Jan;25(1):192-205
pubmed: 20847229
Circ Res. 2013 Apr 26;112(9):1234-43
pubmed: 23524588
Am J Transl Res. 2009;1(1):62-71
pubmed: 19966939
Cancer Res. 2008 Dec 1;68(23):9589-94
pubmed: 19047134
Cancer Lett. 2013 Oct 28;340(1):72-81
pubmed: 23851184
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 May;1862(5):496-512
pubmed: 28111285
Acta Pharm Sin B. 2015 Mar;5(2):135-44
pubmed: 26579439
Oncotarget. 2016 Jan 12;7(2):1096-106
pubmed: 26701854
Hepatology. 2017 Mar;65(3):893-906
pubmed: 28102638
Cancer Res. 2011 Jul 1;71(13):4628-39
pubmed: 21565979
Mol Cancer Res. 2007 Oct;5(10):981-9
pubmed: 17951399
PLoS One. 2012;7(11):e50013
pubmed: 23166811
Oncogene. 2006 Aug 7;25(34):4725-43
pubmed: 16892086
Br J Cancer. 2010 Oct 12;103(8):1215-20
pubmed: 20842113
PLoS One. 2016 Feb 03;11(2):e0148433
pubmed: 26840408
Mol Cell Biol. 2004 Nov;24(22):9705-25
pubmed: 15509776
Cell. 2004 Feb 20;116(4):527-40
pubmed: 14980220
PLoS One. 2011;6(5):e20291
pubmed: 21629773
EMBO J. 2002 Jun 3;21(11):2672-81
pubmed: 12032080
J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):91-100
pubmed: 21167281
Curr Opin Gastroenterol. 2015 Mar;31(2):159-65
pubmed: 25584736
Cancer Lett. 2015 Jan 28;356(2 Pt B):410-7
pubmed: 25304371
Biochem Pharmacol. 2014 Oct 15;91(4):483-9
pubmed: 25175738
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11295-300
pubmed: 9326603
Biochem Pharmacol. 2011 Apr 1;81(7):910-6
pubmed: 21241664
Biochem Pharmacol. 2013 Apr 1;85(7):1007-17
pubmed: 23396089
Am J Physiol Gastrointest Liver Physiol. 2014 Jul 15;307(2):G205-18
pubmed: 24833708
Oncogene. 2006 May 18;25(21):2974-86
pubmed: 16434970
J Cancer Res Clin Oncol. 2012 Aug;138(8):1355-61
pubmed: 22484852
Hepatology. 2011 Mar;53(3):865-74
pubmed: 21319187
J Biol Chem. 2015 Mar 6;290(10):6507-15
pubmed: 25596928
Cancer Res. 2010 Sep 1;70(17):6824-36
pubmed: 20660371
Immunity. 2014 Jan 16;40(1):128-39
pubmed: 24412617
Virchows Arch. 2011 Aug;459(2):129-39
pubmed: 21713366
Cell Death Differ. 2005 Apr;12(4):395-404
pubmed: 15665816
Clin Transl Gastroenterol. 2017 Jun 29;8(6):e103
pubmed: 28662021
Clin Cancer Res. 2005 May 1;11(9):3558-66
pubmed: 15867260
Oncogene. 2010 Sep 2;29(35):4980-8
pubmed: 20562918